Financial Performance - The company's operating revenue for the first half of 2021 was ¥1,686,683,763.22, representing a 54.01% increase compared to ¥1,095,177,753.22 in the same period last year[10]. - The net profit attributable to shareholders of the listed company was ¥149,638,735.39, a significant increase of 278.10% from a loss of ¥84,020,007.46 in the previous year[10]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥107,986,509.04, up 202.59% from a loss of ¥105,261,773.21 in the same period last year[10]. - The net cash flow from operating activities reached ¥2,033,077,482.96, marking a 463.98% increase from ¥360,489,007.66 in the previous year[10]. - Basic and diluted earnings per share were both ¥0.2320, compared to a loss of ¥0.1295 per share in the same period last year, reflecting a 279.15% improvement[10]. - The total operating revenue for the first half of 2021 was CNY 1,686,683,763.22, representing a year-on-year increase of 54.01% compared to CNY 1,095,177,753.22 in the same period last year[21]. - Revenue from the pharmaceutical industry accounted for 93.17% of total revenue, amounting to CNY 1,571,567,090.21, with a year-on-year growth of 79.11%[21]. - The company reported a significant increase in investment income, reaching CNY 27,492,715.40, up 741.05% from CNY 3,268,849.22 in the previous year[20]. - The company reported a total profit of ¥251,712,817.06 for the first half of 2021, compared to a loss of ¥10,232,157.81 in the first half of 2020[85]. - The total comprehensive income for the first half of 2021 was ¥223,827,420.87, compared to ¥302,193.29 in the first half of 2020, showing a strong recovery[86]. Assets and Liabilities - The total assets at the end of the reporting period were ¥11,256,186,598.67, a 2.80% increase from ¥10,950,024,729.95 at the end of the previous year[10]. - The company's total liabilities were reported at 1,549,420,209.67 yuan, compared to 1,173,013,575.53 yuan at the end of the previous year[76]. - The total current assets increased to 8,146,957,226.67 yuan from 7,773,128,605.06 yuan year-over-year[75]. - The company's total liabilities increased to ¥1,495,125,635.63 from ¥1,045,434,910.62, reflecting a rise of about 43%[80]. - The company's cash and cash equivalents reached 2,725,352,278.36 yuan, up from 1,452,295,049.08 yuan at the end of 2020[74]. - The company's inventory decreased to ¥2,029,323,200.58, accounting for 18.03% of total assets, down from 22.63% last year, a 4.60% decrease[23]. - The company reported a decrease in accounts receivable to 418,040,008.99 yuan from 469,028,451.33 yuan at the end of 2020[74]. - The company’s total liabilities include a significant portion attributed to lease liabilities, reflecting the impact of the new leasing standards[170]. Market and Product Development - The company has established a digital transformation advantage by integrating big data, mobile internet, cloud computing, and artificial intelligence to enhance production and marketing efficiency[18]. - The company is focusing on product development to cater to younger consumers and exploring ready-to-eat products[31]. - The company is actively expanding its market presence and product offerings, leveraging its historical roots and innovative approaches to meet evolving consumer demands[16]. - The company is focusing on expanding its product categories and enhancing its product technology barriers through continuous pharmacological and clinical research[32]. - The company has developed over 40 strategic reserve products, including the "Peach Blossom Princess" Ejiao cake and the "True Face" brand series targeting the female beauty market[17]. Corporate Governance and Compliance - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[2]. - The company has not engaged in any asset or equity acquisitions or sales during the reporting period[42]. - The company has not faced any penalties or rectification requirements during the reporting period[42]. - The company has not implemented any employee stock ownership plans or other incentive measures during the reporting period[35]. - The company has no significant litigation or arbitration matters during the reporting period[42]. Environmental and Social Responsibility - The company has established two wastewater treatment facilities to ensure compliance with environmental standards, with no reported violations[37]. - The company has conducted environmental risk assessments and established emergency response plans for potential environmental incidents[38]. - The company has a strong focus on customer experience and product quality, aiming to combine traditional Chinese medicine with modern health awareness[16]. Financial Management and Investments - The company has engaged in entrusted wealth management with a total amount of RMB 296,000,000, with an outstanding balance of RMB 220,000,000[48]. - The expected annualized return for entrusted wealth management products ranges from 2.54% to 3.60%[51]. - The company has expanded its financial product offerings, including a non-principal floating return product with a value of 10,000 million and a return of 3.50%[54]. - The company reported cash inflow from sales of goods and services of CNY 2,919,270,210.36, compared to CNY 1,542,641,942.83 in the previous year, reflecting a growth of about 89%[87]. Accounting Policies and Financial Reporting - The financial statements are prepared based on the "Enterprise Accounting Standards" issued by the Ministry of Finance, ensuring compliance and accuracy[106]. - The company recognizes financial instruments upon entering into contracts, ensuring proper asset and liability management[118]. - The company applies the expected credit loss model for impairment of financial assets, assessing credit risk at each reporting date to determine the appropriate loss allowance[125]. - The company recognizes significant receivables based on the aging analysis, with provisions ranging from 5% for receivables within one year to 100% for those over three years[129][133]. - The company’s accounting policy change regarding leasing was approved on March 18, 2021, and is effective from January 1, 2021[169].

[Important Notice](index=2&type=section&id=Item%201.%20Important%20Notice) The company's board of directors, supervisory board, and senior management ensure the truthfulness, accuracy, and completeness of this quarterly report, with all directors attending the review meeting - The company's Board of Directors, Supervisory Board, and all senior management guarantee the truthfulness, accuracy, and completeness of this quarterly report, assuming corresponding legal responsibilities, with all directors present at the review meeting[2](index=2&type=chunk) [Basic Company Information](index=3&type=section&id=Item%202.%20Basic%20Company%20Information) This section provides an overview of the company's key financial data, performance indicators, and shareholder structure [Key Accounting Data and Financial Indicators](index=3&type=section&id=II.I.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) The company achieved a significant turnaround in Q1 2021, with revenue growing by **67.56%**, net profit attributable to shareholders shifting from a loss of **CNY 83.87 million** to a profit of **CNY 61.65 million**, and operating cash flow improving by over **400%** Key Financial Indicators for Q1 2021 | Indicator | Current Period | Prior Year Period | Year-over-Year Change | | :--- | :--- | :--- | :--- | | Operating Revenue (CNY) | 733,470,888.88 | 437,737,253.85 | 67.56% | | Net Profit Attributable to Shareholders (CNY) | 61,648,968.09 | -83,867,522.88 | 173.51% | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) (CNY) | 44,656,345.07 | -93,809,543.32 | 147.60% | | Net Cash Flow from Operating Activities (CNY) | 1,105,787,345.67 | 216,072,249.65 | 411.77% | | Basic Earnings Per Share (CNY/share) | 0.0956 | -0.1291 | 174.04% | | Total Assets (CNY) | 11,195,609,873.89 | - | 2.24% (vs. end of previous year) | | Net Assets Attributable to Shareholders (CNY) | 9,792,002,112.46 | - | 0.62% (vs. end of previous year) | - During the reporting period, the company's non-recurring gains and losses totaled **CNY 16.99 million**, primarily from government subsidies, fair value changes, and investment income from transactional financial assets[4](index=4&type=chunk) [Shareholder Information](index=4&type=section&id=II.II.%20Total%20Shareholders%20and%20Top%20Ten%20Shareholders%20at%20Period%20End) As of the end of the reporting period, the company had **78,165** common shareholders, with China Resources Dong-E-E-Jiao Co., Ltd. and its concerted party, China Resources Pharmaceutical Investment Co., Ltd., collectively holding **32%** of the shares as the controlling shareholders Top Three Shareholders' Holdings | Shareholder Name | Shareholder Type | Holding Percentage | Number of Shares Held | | :--- | :--- | :--- | :--- | | China Resources Dong-E-E-Jiao Co., Ltd. | State-owned Legal Person | 23.14% | 151,351,731 | | Hong Kong Securities Clearing Company Limited | Overseas Legal Person | 9.61% | 62,841,182 | | China Resources Pharmaceutical Investment Co., Ltd. | State-owned Legal Person | 8.86% | 57,935,116 | - China Resources Dong-E-E-Jiao Co., Ltd. and China Resources Pharmaceutical Investment Co., Ltd. are concerted parties, collectively holding **209,286,847** shares, representing **32%** of the company's total share capital[7](index=7&type=chunk) [Significant Events](index=6&type=section&id=Item%203.%20Significant%20Events) This section details significant financial data changes, share repurchase progress, entrusted wealth management activities, and investor relations engagements [Analysis of Major Financial Data Changes](index=6&type=section&id=III.I.%20Changes%20and%20Reasons%20for%20Major%20Financial%20Data%20and%20Indicators%20During%20the%20Reporting%20Period) During the reporting period, the company experienced significant changes in multiple financial indicators, with revenue growth driven by digital transformation, a substantial decrease in financial expenses due to increased interest income, and higher inventory impairment provisions - Operating revenue increased by **67.56%** year-over-year, primarily due to the company's digital transformation initiatives driving sales growth[11](index=11&type=chunk) - Financial expenses decreased by **191.07%** year-over-year, mainly influenced by increased interest income and reduced interest expenses during the period[11](index=11&type=chunk) - Asset impairment losses surged by **3,240.17%** year-over-year, primarily due to increased inventory impairment provisions during the period[11](index=11&type=chunk) - Contract liabilities increased by **73.91%** compared to the beginning of the year, reflecting an increase in advance receipts for goods and indicating positive future sales momentum[11](index=11&type=chunk) [Share Repurchase Progress](index=7&type=section&id=III.II.%20Progress%2C%20Impact%2C%20and%20Solutions%20Analysis%20of%20Significant%20Events) The report details the company's share repurchase plan, initiated in 2019 and terminated in June 2020, which ultimately repurchased approximately **10.04 million** shares, accounting for **1.54%** of total share capital, for a total cost of approximately **CNY 350 million** - The company's share repurchase proposal was approved in May 2019 and subsequently terminated by the Board of Directors on June 12, 2020[13](index=13&type=chunk)[15](index=15&type=chunk) - As of the end of February 2020, the company had cumulatively repurchased **10,044,713** shares, representing **1.54%** of the total share capital, with a total payment of **CNY 349,823,302.72**[14](index=14&type=chunk) [Entrusted Wealth Management](index=9&type=section&id=III.VIII.%20Entrusted%20Wealth%20Management) During the reporting period, the company actively engaged in entrusted wealth management using its own funds, with transactions totaling **CNY 1.41 billion** and an outstanding balance of **CNY 2.11 billion** at period-end, primarily in low-risk bank wealth management products and structured deposits Overview of Entrusted Wealth Management (Unit: CNY 10,000) | Source of Funds | Amount of Entrusted Wealth Management Transactions | Outstanding Balance | Overdue Unrecovered Amount | | :--- | :--- | :--- | :--- | | Own Funds | 141,000 | 211,000 | 0 | - The company's wealth management investments consist of non-principal-protected floating-rate products or principal-protected floating-rate structured deposits issued by banks, with expected annualized returns ranging from **2.54%** to **3.90%**[21](index=21&type=chunk)[22](index=22&type=chunk)[23](index=23&type=chunk) [Investor Relations Activities](index=13&type=section&id=III.XI.%20Registration%20Form%20for%20Investor%20Research%2C%20Communication%2C%20and%20Interview%20Activities%20During%20the%20Reporting%20Period) During the reporting period, the company engaged in a telephone communication session with investors on March 31, 2021, primarily discussing corporate strategy and operational performance - The company held a telephone communication meeting on March 31, 2021, engaging with individual investors to discuss corporate strategy and operational status[25](index=25&type=chunk) [Financial Statements](index=14&type=section&id=Item%204.%20Financial%20Statements) This section presents the company's unaudited financial statements for the first quarter, including details on accounting standard changes and the audit status [Financial Statement Details](index=14&type=section&id=IV.I.%20Financial%20Statements) This section provides the company's unaudited consolidated and parent company balance sheets, income statements, and cash flow statements for Q1 2021 - This section includes detailed financial statements as of March 31, 2021, comprising consolidated and parent company balance sheets, income statements, and cash flow statements[26](index=26&type=chunk)[31](index=31&type=chunk)[34](index=34&type=chunk)[37](index=37&type=chunk)[39](index=39&type=chunk)[42](index=42&type=chunk) [Accounting Standard Change Adjustments](index=26&type=section&id=IV.II.%20Explanation%20of%20Financial%20Statement%20Adjustments) Effective January 1, 2021, the company adopted new lease accounting standards, retrospectively adjusting financial statements at the initial application date to recognize right-of-use assets and lease liabilities, and adjusting retained earnings accordingly, without restating comparative period information - The company adopted the newly revised 'Accounting Standard for Business Enterprises No. 21 – Leases' effective January 1, 2021, and made corresponding adjustments to its opening financial statements[49](index=49&type=chunk) Major Impact of New Lease Standards on Opening Consolidated Balance Sheet | Adjustment Item | Adjustment Amount (CNY) | | :--- | :--- | | Right-of-Use Assets | +25,440,564.02 | | Lease Liabilities | +27,479,317.94 | | Deferred Income Tax Assets | +984,105.27 | | Undistributed Profits | -1,054,648.65 | [Audit Opinion](index=30&type=section&id=IV.III.%20Audit%20Report) The company's Q1 2021 report is unaudited - The company's first-quarter report is unaudited[51](index=51&type=chunk)

Financial Performance - The company's operating revenue for 2020 was ¥3,409,437,164.01, representing a 14.79% increase compared to ¥2,970,075,665.15 in 2019[16] - The net profit attributable to shareholders was ¥43,289,251.31, a significant recovery from a loss of ¥454,830,581.98 in the previous year, marking a 109.52% improvement[16] - The net cash flow from operating activities was ¥800,834,183.65, a 171.55% increase from a negative cash flow of ¥1,119,993,996.91 in 2019[16] - Basic earnings per share improved to ¥0.07 from a loss of ¥0.68 in 2019, reflecting a 110.00% increase[16] - The total revenue for 2020 was ¥3,409,437,164.01, representing a year-on-year increase of 14.79% compared to ¥2,970,075,665.15 in 2019[40] - The pharmaceutical industry contributed ¥3,002,126,133.81, accounting for 88.05% of total revenue, with a significant year-on-year growth of 43.61%[40] - The company reported a significant reduction in non-recurring losses, with the net profit excluding non-recurring items at -¥39,462,110.08, an improvement of 92.65% from -¥536,791,921.24 in 2019[16] - The company reported a cash dividend payout ratio of 808.75% of its net profit for 2020[88] Assets and Liabilities - Total assets at the end of 2020 were ¥10,950,024,729.95, a decrease of 6.43% from ¥11,702,477,592.24 in 2019[17] - The net assets attributable to shareholders decreased by 2.50% to ¥9,731,407,793.03 from ¥9,980,806,584.28 in 2019[17] - As of the end of 2020, cash and cash equivalents amounted to ¥1,452,295,049.08, representing 13.26% of total assets, a decrease of 3.20% from the previous year[61] - Accounts receivable decreased to ¥469,028,451.33, accounting for 4.28% of total assets, down 8.44% due to increased collection efforts[61] - Inventory stood at ¥2,477,620,936.06, making up 22.63% of total assets, a reduction of 7.53% attributed to increased sales[61] Operational Highlights - The company launched new products including "Zhenyan" series targeting the beauty market and "Aojiao Powder" which was significantly upgraded and launched in 2020[25][26] - The company achieved a 100% pass rate in national quality inspections over the past 69 years, ensuring product authenticity and quality[30] - The company has been recognized as the top brand in the Chinese medicine industry for six consecutive years, reinforcing its market leadership[30] - The company launched over 10 new consumption methods for its products, including "Ejiao powder + yogurt," enhancing convenience and consumer experience[35] - The company has developed new products including 9 types of medicinal pastes and 5 types of bird's nest products, successfully launched in the market[35] Market and Sales - The sales volume of the pharmaceutical industry reached 7,019 tons, an increase of 25.14% from 5,609 tons in 2019[44] - The revenue from the East China region was ¥1,515,772,559.51, making up 44.46% of total revenue, with a growth of 10.60% year-on-year[40] - The company reported a 59.90% decline in revenue from donkey breeding and trade, which generated ¥296,290,039.69 in 2020[40] Digital Transformation and Innovation - The digital transformation strategy implemented during the pandemic allowed the company to enhance customer engagement and operational efficiency through digital platforms[32] - The company is focusing on digital marketing and customer experience to drive growth, transitioning from traditional marketing strategies[35] - The company aims to enhance customer engagement and retention through improved data operations and marketing automation[74] - The company plans to build a consumer data platform to transform its business model and focus on consumer asset operations, aiming for a second growth curve[77] Research and Development - The company has established a unique national engineering research center for gelatinous traditional Chinese medicine, leading to over 160 authorized patents and multiple national research projects[31] - The company achieved significant breakthroughs in molecular breeding of the Dong'e black donkey, with research published in the journal "Nature Communications"[56] - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product efficacy[165] Corporate Governance - The company strictly adheres to corporate governance regulations and has established a complete governance structure[180] - The company has established four specialized committees under the board: Strategic Committee, Nomination Committee, Audit Committee, and Compensation and Assessment Committee, ensuring effective governance and decision-making processes[182] - The company’s independent directors have attended all board meetings and shareholder meetings, demonstrating their active participation in governance[187] Shareholder Information - The largest shareholder, China Resources Dong'e Ejiao Co., Ltd., holds 23.14% of the shares, totaling 151,351,731 shares[144] - The second-largest shareholder, China Resources Pharmaceutical Investment Co., Ltd., holds 8.86% of the shares, totaling 57,935,116 shares[144] - The company has a total of 72,054 common shareholders as of the end of the reporting period[144] Environmental and Social Responsibility - The company has established two wastewater treatment facilities to manage wastewater from production processes, ensuring compliance with environmental standards[131] - The company has achieved a 100% monitoring rate for wastewater, waste gas, and noise emissions, demonstrating its commitment to environmental protection[132] - The company has actively engaged in poverty alleviation through technology-driven initiatives, enhancing the skills of impoverished laborers and promoting long-term income growth[129] Financial Management - The company has engaged in multiple financial management products with a total investment of 10,000 million CNY to 20,000 million CNY, demonstrating a strategic approach to liquidity management[117][118] - The expected returns from these financial products range from 3.10% to 3.82%, reflecting a conservative investment strategy[117][118] - The company has successfully recovered the principal amounts from all financial products, ensuring no losses during the reporting period[117][118]

Financial Performance - The company's operating revenue for the reporting period was ¥1,095,177,753.22, a decrease of 42.06% compared to the same period last year, which was ¥1,890,344,562.13[10]. - The net profit attributable to shareholders of the listed company was -¥84,020,007.46, representing a decline of 143.54% from the previous year's profit of ¥192,963,719.27[10]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥105,261,773.21, down 173.14% from ¥143,923,347.62 in the same period last year[10]. - The net cash flow from operating activities was ¥360,489,007.66, an increase of 136.94% compared to -¥975,818,494.29 in the previous year[10]. - The total assets at the end of the reporting period were ¥11,194,805,066.24, a decrease of 3.94% from ¥11,653,674,527.93 at the end of the previous year[10]. - The net assets attributable to shareholders of the listed company were ¥9,618,284,812.16, down 3.58% from ¥9,974,925,867.75 at the end of the previous year[10]. - The company reported a significant increase in asset impairment losses, which rose by 1092.74% to ¥12,726,462.34 from ¥1,066,992.56 year-on-year[21]. - The company’s total cash and cash equivalents decreased by 70.35% to a net increase of ¥-111,898,679.47 from ¥-377,446,858.80 in the previous year[21]. - The company’s total operating revenue for the first half of 2020 was ¥1,095,177,753.22, a decrease of 42.0% compared to ¥1,890,344,562.13 in the same period of 2019[87]. - The net profit for the first half of 2020 was a loss of ¥85,201,635.93, compared to a profit of ¥192,168,319.43 in the first half of 2019[88]. Product Development and Innovation - The company launched new products in 2020, including "instant drink" Ejiao powder, targeting convenience and fashion[14]. - The company has developed over 20 new products, including Dong'e Ejiao Powder and instant soluble blocks, enhancing product structure and industry upgrade[18]. - The company emphasizes a differentiated product layout and innovation in research and development to reshape market order, focusing on convenience and ready-to-eat consumption experiences[39]. - The company has invested 100 million RMB in research and development for innovative technologies aimed at improving product quality and customer satisfaction[115]. Market Strategy and Customer Engagement - The company achieved significant breakthroughs in online sales through deep cooperation with pharmaceutical e-commerce platforms, driving innovative growth[18]. - The company emphasizes digital marketing transformation, focusing on customer operations and utilizing content creation and live streaming[18]. - The company plans to enhance customer cooperation by upgrading from a transactional relationship to a service-oriented relationship, aiming for customer growth and retention[39]. - The company plans to enhance its digital marketing efforts, allocating an additional 50 million RMB to boost online sales channels and customer engagement[115]. Financial Management and Investments - The company’s investment cash flow net amount was negative at ¥342,478,500.31, a decline of 145.82% compared to ¥747,516,725.63 in the previous year[21]. - The company has engaged in various bank financial products with expected annualized returns ranging from 2.80% to 3.82%[49]. - The total amount of entrusted financial products reached CNY 133 million, with an average return rate of 3.80%[50]. - The company has invested RMB 70 million in entrusted financial management, with an outstanding balance of RMB 93 million[48]. Environmental and Social Responsibility - The company has established two wastewater treatment facilities, ensuring compliance with discharge standards, with COD and ammonia nitrogen emissions well below regulatory limits[52]. - The company has supported over 21,700 farming households, providing 4,876 job opportunities and increasing farmers' income by over 20% through its poverty alleviation initiatives[54]. - The company has implemented poverty alleviation projects, directly benefiting 1,218 registered poor households and 2,570 individuals, with an average income increase of 1,400 RMB per person[58]. - The company has actively engaged in environmental risk assessments and established emergency response plans for environmental incidents[53]. Shareholder and Corporate Governance - The company has not distributed cash dividends or bonus shares for the half-year period, nor has it increased share capital from capital reserves[41]. - The company announced a share buyback plan on May 25, 2019, with subsequent disclosures regarding the progress of the buyback until June 2020[65]. - As of February 2020, the company has repurchased a total of 10,044,713 shares, accounting for 1.54% of the total share capital, with a total payment of 349.82 million RMB[64]. - The company terminated the share buyback program on June 12, 2020, following a board meeting resolution[66]. Risk Factors - The company faced long-term risks due to a declining supply of donkeys and short-term risks from the COVID-19 pandemic affecting sales[38]. - The company has not experienced any major litigation or arbitration matters during the reporting period[43]. - The company has not undergone any bankruptcy reorganization during the reporting period[43]. Accounting and Financial Reporting - The financial report for the first half of 2020 was not audited, which may affect the reliability of the financial data presented[79]. - The company’s financial statements were prepared in accordance with the accounting standards issued by the Ministry of Finance, ensuring compliance and accuracy[110]. - The company has not made any changes to significant accounting policies or estimates in the reporting period[163]. - The company recognizes revenue based on the expected value or most likely amount for variable consideration, such as sales rebates[157].

Financial Performance - The company's revenue for Q1 2020 was ¥437,737,253.85, a decrease of 66.11% compared to ¥1,291,783,493.19 in the same period last year[3] - The net profit attributable to shareholders was -¥83,867,522.88, representing a decline of 121.33% from ¥393,179,922.82 year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥93,809,543.32, down 125.48% from ¥368,111,454.11 in the previous year[3] - The net profit for Q1 2020 was a loss of CNY 91,252,572.15, compared to a profit of CNY 471,179,577.73 in the same period last year[31] - The total comprehensive income for the first quarter was -84,197,169.43 CNY, compared to 374,012,876.56 CNY in the same period last year[32] - The net profit for the first quarter of 2020 was -84,197,169.43 CNY, a significant decrease from 389,948,990.41 CNY in the same period last year[32] Cash Flow - The net cash flow from operating activities improved to ¥216,072,249.65, a 134.15% increase from -¥632,632,219.50 in the same period last year[3] - The net cash flow from operating activities was 216,072,249.65 CNY, a significant improvement compared to -632,632,219.50 CNY in the previous period[36] - The total cash outflow from operating activities was 670,117,035.68 CNY, compared to 1,581,636,533.53 CNY in the previous period[36] - The cash inflow from investment activities was significantly lower than the previous period, which was 2,057,884,767.36 CNY[36] - The net cash flow from financing activities was -128,885,377.90 CNY, compared to -6,301,908.09 CNY in the previous period[37] - The total cash and cash equivalents at the end of the period amounted to 1,955,914,760.92 CNY, up from 1,926,052,316.22 CNY in the previous period[37] Assets and Liabilities - The total assets at the end of the reporting period were ¥11,096,986,612.25, a decrease of 4.78% from ¥11,653,674,527.93 at the end of the previous year[3] - The total current assets decreased to ¥7,640,676,324.78 from ¥8,194,201,087.88, representing a decline of about 6.8%[23] - The total liabilities decreased from ¥1,630,611,386.48 to ¥1,280,704,318.12, reflecting a reduction of about 21.5%[25] - The company's total assets as of March 31, 2020, were CNY 11,258,615,858.37, a decrease from CNY 11,491,856,219.50 at the end of 2019[29] - The total liabilities as of March 31, 2020, were CNY 1,428,624,286.65, slightly down from CNY 1,443,237,236.23 at the end of 2019[29] Shareholder Information - The top two shareholders, China Resources Dong'e Ejiao Co., Ltd. and China Resources Pharmaceutical Investment Co., Ltd., held 23.14% and 8.86% of the shares, respectively[7] - The total number of ordinary shareholders at the end of the reporting period was 92,890[6] - The total equity attributable to shareholders of the parent company was CNY 9,829,991,571.72, a decrease from CNY 10,048,618,983.27 at the end of 2019[29] Operating Costs and Expenses - Operating costs decreased by 31.90% to RMB 290.53 million from RMB 426.59 million in the previous period, reflecting lower sales[12] - The company reported a 62.68% reduction in taxes payable, amounting to RMB 18.63 million compared to RMB 49.92 million in the previous period[12] - The company’s financial expenses increased significantly by 209.66%, resulting in a loss of RMB 5.37 million due to reduced interest income and exchange rate declines[12] - The company’s investment income dropped by 75.50% to RMB 508,277.77 from RMB 2.07 million in the previous period, primarily due to decreased returns from financial products[12] - The company's operating expenses, including sales and management costs, saw significant reductions due to the pandemic, with sales expenses down by 52.19%[12] Other Financial Metrics - The basic earnings per share were -¥0.1291, down 121.47% from ¥0.6012 in the same period last year[3] - The weighted average return on equity was -0.79%, a decline of 4.21% from 3.42% year-on-year[3] - Research and development expenses were 35,605,925.73 CNY, a decrease of 43.3% from 62,758,422.27 CNY in the prior year[33] - The gross profit margin decreased, with cost of goods sold at 126,575,604.74 CNY compared to 299,282,085.53 CNY in the previous year[33]

Financial Performance - In 2019, the company's operating revenue was ¥2,958,622,339.62, a decrease of 59.68% compared to ¥7,338,316,223.18 in 2018[16] - The net profit attributable to shareholders was -¥443,915,811.52, representing a decline of 121.29% from ¥2,084,866,052.69 in the previous year[16] - The net cash flow from operating activities was -¥1,119,993,996.91, a drop of 211.00% compared to ¥1,009,049,053.07 in 2018[16] - The total assets at the end of 2019 were ¥11,653,674,527.93, down 15.98% from ¥13,869,959,247.35 at the end of 2018[16] - The net assets attributable to shareholders decreased by 11.74% to ¥9,974,925,867.75 from ¥11,302,058,975.94 in 2018[16] - The basic earnings per share were -¥0.68, a decline of 121.32% from ¥3.19 in 2018[16] - The weighted average return on equity was -4.13%, a decrease of 23.85% from 19.72% in the previous year[16] - The total revenue for 2019 was approximately ¥2.96 billion, a decrease of 59.68% compared to ¥7.34 billion in 2018[40] - The pharmaceutical industry revenue accounted for 69.95% of total revenue, totaling approximately ¥2.07 billion, down 67.61% from ¥6.39 billion in 2018[41] - The sales volume of the pharmaceutical industry decreased by 32.09% to 5,561 tons in 2019, compared to 8,188 tons in 2018[45] Cash Flow and Investments - The net cash flow from operating activities decreased by 211% to -CNY 1,119,993,996.91, primarily due to a reduction in cash received from sales[59] - Investment activities generated a net cash flow of CNY 1,836,558,933.30, an increase of 2,764.57% compared to CNY 64,112,913.74 in 2018[58] - The company reported a significant increase in investment, with total investments of ¥8,238,800.00, a 311.94% increase compared to ¥2,000,000.00 in the previous year[66] - The company has successfully recovered all principal amounts from its financial investments during the reporting period, indicating effective risk management[115] - The company is actively managing its financial investments to optimize returns while maintaining a focus on liquidity and risk[115] Research and Development - The company has established multiple technology platforms, including a national engineering technology research center for traditional Chinese medicine, enhancing its R&D capabilities[36] - The company has completed the development of 35 enterprise standards and obtained 58 authorized patents, promoting the transformation of the donkey breeding industry[37] - Research and development expenses totaled CNY 205,374,091.23, a decrease of 14.71% from CNY 240,803,070.08 in 2018[54] - The number of R&D personnel increased by 13.09% to 432, with R&D expenses accounting for 6.96% of operating revenue[56] - The research and development focus includes enhancing product efficacy studies and developing trendy, convenient ejiao products for younger consumers[79] Market Strategy and Product Development - The company is actively pursuing digital transformation, new product development, and establishing industry standards to enhance competitiveness[33] - The company has launched a new fresh ready-to-eat Ejiao product, targeting new consumer trends and expanding its market presence[35] - The company is enhancing the competitiveness of the donkey breeding industry to ensure sustainable raw material supply[80] - The company plans to strengthen clinical academic research and develop differentiated products that cater to consumer preferences for convenience and ready-to-eat options[74] - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by the end of the fiscal year[174] Corporate Governance and Shareholder Relations - The company has adhered to its cash dividend policy as outlined in its articles of association, ensuring the protection of minority shareholders' rights[85] - The company has implemented changes in accounting policies in accordance with the new financial instruments standards effective from January 1, 2019[92] - The company maintains a clear separation from its controlling shareholder in terms of business, personnel, assets, institutions, and finance, ensuring operational independence[197] - The company has a well-defined mechanism for selecting its management team, ensuring responsibilities are clearly delineated[196] - The company has not experienced any significant discrepancies in governance practices compared to the regulatory requirements set by the China Securities Regulatory Commission[196] Environmental and Social Responsibility - The company has constructed two wastewater treatment facilities to handle wastewater from its production processes, ensuring compliance with environmental standards[135] - The company has achieved a 100% monitoring rate for wastewater, waste gas, and noise emissions, with all parameters meeting regulatory standards[139] - The company has provided employment for 4,876 individuals through its poverty alleviation initiatives in the donkey breeding industry, resulting in a 20% increase in income for farmers[129] - A total of 120,000 yuan was allocated for poverty alleviation funds, and 300,000 yuan for material support, helping 75,709 registered impoverished individuals to escape poverty[131] - The company has actively engaged in environmental risk assessments and has established emergency response plans for environmental incidents[138] Share Repurchase and Capital Structure - The company plans to repurchase shares with a total amount not less than RMB 750 million and not exceeding RMB 1.5 billion, with a maximum repurchase price of RMB 45 per share[146] - As of December 31, 2019, the total repurchased shares amounted to 6,174,237, which is 0.94% of the total share capital, with a total payment of RMB 227,337,663.91[147] - The company has disclosed multiple announcements regarding the share repurchase progress from May 2019 to February 2020, ensuring compliance with regulations[149] - The total number of ordinary shareholders at the end of the reporting period was 89,404, an increase from 88,455 at the end of the previous month[152] - The company has a total share capital of 654,021,537 shares, with 99.98% being unrestricted shares[145] Leadership and Management Changes - The company appointed Han Yuewei as the new chairman on December 9, 2019, following the resignation of Wang Chuncheng[167] - The company has seen a change in its board with the appointment of new directors and supervisors, including Wu Jun and Weng Jingwen[167] - The management team has a diverse background with experience in various sectors, which is expected to drive the company's growth strategy[170] - The company is focusing on expanding its market presence and enhancing its product offerings through strategic appointments and leadership changes[168] - The company is committed to maintaining its leadership in the industry by leveraging the expertise of its senior management team[170]

Financial Performance - The company's operating revenue for the first half of 2019 was ¥1,890,344,562.13, a decrease of 36.69% compared to ¥2,985,982,356.58 in the same period last year[9]. - The net profit attributable to shareholders was ¥192,963,719.27, down 77.62% from ¥862,252,709.27 year-on-year[9]. - The net profit after deducting non-recurring gains and losses was ¥143,923,347.62, representing an 81.55% decline from ¥780,033,714.98 in the previous year[9]. - The basic earnings per share decreased to ¥0.3537, a drop of 73.17% compared to ¥1.3184 in the same period last year[9]. - The total revenue from the ejiao product line was ¥1,493,115,645.71, a decrease of 36.29% year-on-year[23]. - The company reported a significant increase in credit impairment losses, rising to ¥47,712,504.32, a 11,310.73% increase from -¥425,596.64[20]. - The company reported a net profit margin of 25%, maintaining a stable financial position despite market fluctuations[120]. Cash Flow and Assets - The net cash flow from operating activities was -¥975,818,494.29, a decrease of 10.67% compared to -¥881,772,977.16 in the previous year[9]. - The company's cash and cash equivalents decreased to ¥1,758,442,684.77 from ¥2,135,939,927.81, reflecting a decline of approximately 17.6%[78]. - The company's cash and cash equivalents at the end of the period amounted to ¥1,758,442,684.77, a decrease from ¥2,135,939,927.81 at the beginning of the period[187]. - The total amount of trading financial assets decreased to ¥1,884,878,747.01 from ¥2,705,864,281.27[188]. - The total accounts receivable amounted to ¥1,682,734,041.24, with a bad debt provision of ¥112,992,043.70, representing 6.71% of the total[197]. Investments and R&D - Research and development investment increased by 47.29% to ¥113,460,350.70, driven by new product development projects[19]. - The company is investing 200 million RMB in research and development for new technologies aimed at enhancing product quality[120]. - The company is actively promoting new product development, including clinical research on the effects of donkey hide gelatin on various health conditions, and has initiated a million-case integrated medical research project for its compound donkey hide gelatin[17]. Market Strategy and Expansion - The company is focusing on expanding its marketing strategies, optimizing channel structures, and exploring new markets, including international expansion[16]. - The company plans to continue adjusting marketing strategies and expanding new channels and markets to drive terminal sales[19]. - Market expansion efforts include entering three new provinces, projected to increase market share by 8%[120]. - A new marketing strategy focusing on digital channels is expected to improve customer engagement by 30%[120]. Corporate Governance and Compliance - The company has not distributed cash dividends or bonus shares for the half-year period[38]. - The company operates under the approval of the Shandong Provincial Reform Commission and has been listed on the Shenzhen Stock Exchange since July 29, 1996[108]. - The financial report for the first half of 2019 was not audited[77]. - The company has complied with relevant laws and regulations regarding the share repurchase[63]. Environmental and Social Responsibility - The company has established two wastewater treatment facilities, ensuring compliance with municipal discharge standards[51]. - The company has implemented a poverty alleviation project with an investment of RMB 10 million, resulting in an average annual income increase of over RMB 1,000 for impoverished households[56]. - The company has helped 130 registered impoverished individuals to escape poverty through its initiatives[57]. Risks and Challenges - The company faces long-term risks due to the declining population of donkeys and the slow progress of large-scale breeding, which may lead to fluctuations in the price of donkey hide, a key raw material[36]. - Short-term risks include macroeconomic pressures and increased market competition, which may affect the company's performance[36]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 99,754, with a significant concentration of shares held by major shareholders[67]. - China Resources Dong'e Ejiao Co., Ltd. holds 23.14% of the shares, making it the largest shareholder[67]. - The company has a total share capital of 654,021,537 shares, with 99.98% being unrestricted shares[61].